Clinical profile and outcome of children with haemophilia A: The Royal Hospital, Oman’s experience

1. Kaneda M, Kawasaki R, Matsumoto N, et al. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A. J Thromb Haemost 2021; 19: 2938–46. doi: 10.1111/jth.15506. KanedaM KawasakiR MatsumotoN Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A J Thromb Haemost 2021 19 2938 46 10.1111/jth.15506 Open DOISearch in Google Scholar

2. Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801–9. doi: 10.1016/S0140-6736(03)13405-8. Bolton-MaggsPHB PasiKJ Haemophilias A and B Lancet 2003 361 1801 9 10.1016/S0140-6736(03)13405-8 Open DOISearch in Google Scholar

3. Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013; 27:179–84. doi: 10.1016/j.blre.2013.06.002. FranchiniM MannucciPM Hemophilia A in the third millennium Blood Rev 2013 27 179 84 10.1016/j.blre.2013.06.002 Open DOISearch in Google Scholar

4. Kulkarni R, Soucie JM. Pediatric hemophilia: a review. Semin Thromb Hemost 2011; 37: 737–44. doi: 10.1055/s-0031-1297164. KulkarniR SoucieJM Pediatric hemophilia: a review Semin Thromb Hemost 2011 37 737 44 10.1055/s-0031-1297164 Open DOISearch in Google Scholar

5. Sidonio RF. “A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH”: Reply to comment. J Thromb Haemost 2022; 20: 1745–6. doi: 10.1111/jth.15726. SidonioRF “A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH”: Reply to comment J Thromb Haemost 2022 20 1745 6 10.1111/jth.15726 Open DOISearch in Google Scholar

6. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: A meta-analytic approach using national registries. Ann Intern Med 2019; 171:540–6. doi: 10.7326/M19-1208. IorioA StonebrakerJS ChambostH Establishing the prevalence and prevalence at birth of hemophilia in males: A meta-analytic approach using national registries Ann Intern Med 2019 171 540 6 10.7326/M19-1208 Open DOISearch in Google Scholar

7. Kulkarni R, Soucie JM, Lusher J, et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project. Haemophilia 2009; 15: 1281–90. doi: 10.1111/j.1365-2516.2009.02074.x. KulkarniR SoucieJM LusherJ Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project Haemophilia 2009 15 1281 90 10.1111/j.1365-2516.2009.02074.x Open DOISearch in Google Scholar

8. Tagliaferri A, Di Perna C, Riccardi F, et al. The natural history of mild haemophilia: a 30-year single centre experience. Haemophilia 2012; 18: 166–74. doi: 10.1111/j.1365-2516.2011.02617.x. TagliaferriA Di PernaC RiccardiF The natural history of mild haemophilia: a 30-year single centre experience Haemophilia 2012 18 166 74 10.1111/j.1365-2516.2011.02617.x Open DOISearch in Google Scholar

9. Balak DMW, Gouw SC, Plug I, et al. Prenatal diagnosis for haemophilia: a nationwide survey among female carriers in the Netherlands. Haemophilia 2012; 18: 584–92. doi: 10.1111/j.1365-2516.2011.02742.x. BalakDMW GouwSC PlugI Prenatal diagnosis for haemophilia: a nationwide survey among female carriers in the Netherlands Haemophilia 2012 18 584 92 10.1111/j.1365-2516.2011.02742.x Open DOISearch in Google Scholar

10. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 8: 1895–902. doi: 10.1111/j.1538-7836.2010.03962.x. ValentinoLA Blood-induced joint disease: the pathophysiology of hemophilic arthropathy J Thromb Haemost 2010 8 1895 902 10.1111/j.1538-7836.2010.03962.x Open DOISearch in Google Scholar

11. Zimmerman B, Valentino LA. Hemophilia: in review. Pediatr Rev 2013; 34: 289–94. doi: 10.1542/pir.34-7-289. ZimmermanB ValentinoLA Hemophilia: in review Pediatr Rev 2013 34 289 94 10.1542/pir.34-7-289 Open DOISearch in Google Scholar

12. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44. doi: 10.1056/NEJMoa067659. Manco-JohnsonMJ AbshireTC ShapiroAD Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia N Engl J Med 2007 357 535 44 10.1056/NEJMoa067659 Open DOISearch in Google Scholar

13. Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700–10. doi: 10.1111/j.1538-7836.2011.04214.x. GringeriA LundinB von MackensenS A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) J Thromb Haemost 2011 9 700 10 10.1111/j.1538-7836.2011.04214.x Open DOISearch in Google Scholar

14. Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013;121:4046–55. https://doi.org/10.1182/blood-2012-09-457036. GouwSC van den BergHM FischerK Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study Blood 2013 121 4046 55 https://doi.org/10.1182/blood-2012-09-457036. Search in Google Scholar

15. Regling K, Callaghan MU, Sidonio R. Managing severe hemophilia A in children: pharmacotherapeutic options. Pediatr Health Med Ther 2022; 13: 27–35. doi: 10.2147/PHMT.S293246. ReglingK CallaghanMU SidonioR Managing severe hemophilia A in children: pharmacotherapeutic options Pediatr Health Med Ther 2022 13 27 35 10.2147/PHMT.S293246 Open DOISearch in Google Scholar

16. Negrier C, Young G, Abdul Karim F, et al. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia 2016; 22: 507–13. doi: 10.1111/hae.12902. NegrierC YoungG Abdul KarimF Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials Haemophilia 2016 22 507 13 10.1111/hae.12902 Open DOISearch in Google Scholar

17. Oudat R, Al-Maharmeh M, Al-Ghrayeb R, Ogeilat T, Mustafa MK. Prevalence of FVIII inhibitors among children with hemophilia A: Experience at the Jordanian Royal Medical Services. Med Arch Sarajevo Bosnia Herzeg 2020; 74: 187–90. doi: 10.5455/medarh.2020.74.187-190. OudatR Al-MaharmehM Al-GhrayebR OgeilatT MustafaMK Prevalence of FVIII inhibitors among children with hemophilia A: Experience at the Jordanian Royal Medical Services Med Arch Sarajevo Bosnia Herzeg 2020 74 187 90 10.5455/medarh.2020.74.187-190 Open DOISearch in Google Scholar

18. Trimble SR, Parker CS, Grant AM, Soucie JM, Reyes N. Assessing emerging infectious threats to blood safety for the blood disorders community. Am J Prev Med 2010; 38: S468–474. doi: 10.1016/j.amepre.2009.12.019. TrimbleSR ParkerCS GrantAM SoucieJM ReyesN Assessing emerging infectious threats to blood safety for the blood disorders community Am J Prev Med 2010 38 S468 474 10.1016/j.amepre.2009.12.019 Open DOISearch in Google Scholar

19. Oldenburg J. Mutation profiling in haemophilia A. Thromb Haemost 2001; 85: 577–9. doi: 10.1055/s-0037-1615636. OldenburgJ Mutation profiling in haemophilia A Thromb Haemost 2001 85 577 9 10.1055/s-0037-1615636 Open DOISearch in Google Scholar

20. Benson G, Auerswald G, Dolan G, et al. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus 2018; 16: 535–44. doi: 10.2450/2017.0150-17. BensonG AuerswaldG DolanG Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management Blood Transfus 2018 16 535 44 10.2450/2017.0150-17 Open DOISearch in Google Scholar

21. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 2016; 388: 187–97. doi: 10.1016/S0140-6736(15)01123-X. PeyvandiF GaragiolaI YoungG The past and future of haemophilia: diagnosis, treatments, and its complications Lancet 2016 388 187 97 10.1016/S0140-6736(15)01123-X Open DOISearch in Google Scholar

22. Pezeshkpoor B, Oldenburg J, Pavlova A. Insights into the molecular genetic of hemophilia A and hemophilia B: The relevance of genetic testing in routine clinical practice. Hamostaseologie 2022; 42: 390–9. doi: 10.1055/a-1945-9429. PezeshkpoorB OldenburgJ PavlovaA Insights into the molecular genetic of hemophilia A and hemophilia B: The relevance of genetic testing in routine clinical practice Hamostaseologie 2022 42 390 9 10.1055/a-1945-9429 Open DOISearch in Google Scholar

23. Owaidah T, Momen AA, Alzahrani H, et al. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program. Medicine (Baltimore) 2017; 96: e5456. doi: 10.1097/MD.0000000000005456. OwaidahT MomenAA AlzahraniH The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program Medicine (Baltimore) 2017 96 e5456 10.1097/MD.0000000000005456 Open DOISearch in Google Scholar

24. Kadhim KAR, Al-Lami FH, Baldawi KH. Epidemiological profile of hemophilia in Baghdad-Iraq. Inquiry 2019; 56: 46958019845280. doi: 10.1177/0046958019845280. KadhimKAR Al-LamiFH BaldawiKH Epidemiological profile of hemophilia in Baghdad-Iraq Inquiry 2019 56 46958019845280. 10.1177/0046958019845280 Open DOISearch in Google Scholar

25. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125: 2038–44. doi: 10.1182/blood-2015-01-528414. OldenburgJ Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens Blood 2015 125 2038 44 10.1182/blood-2015-01-528414 Open DOISearch in Google Scholar

26. Rehill AM, McCluskey S, O’Donnell JS, et al. Heterogeneity in bleeding tendency and arthropathy development in individuals with hemophilia. Semin Thromb Hemost 2021; 47: 183–91. doi: 10.1055/s-0041-1723769. RehillAM McCluskeyS O’DonnellJS Heterogeneity in bleeding tendency and arthropathy development in individuals with hemophilia Semin Thromb Hemost 2021 47 183 91 10.1055/s-0041-1723769 Open DOISearch in Google Scholar

27. Gringeri A, von Mackensen S, Auerswald G, et al. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia 2004; 10 Suppl 1: 26–33. doi: 10.1111/j.1355-0691.2004.00876.x. GringeriA von MackensenS AuerswaldG Health status and health-related quality of life of children with haemophilia from six West European countries Haemophilia 2004 10 Suppl 1 26 33 10.1111/j.1355-0691.2004.00876.x Open DOISearch in Google Scholar

28. Plug I, van der Bom JG, Peters M, et al. Thirty years of hemophilia treatment in the Netherlands, 1972–2001. Blood 2004; 104: 3494–500. doi: 10.1182/blood-2004-05-2008. PlugI van der BomJG PetersM Thirty years of hemophilia treatment in the Netherlands, 1972–2001 Blood 2004 104 3494 500 10.1182/blood-2004-05-2008 Open DOISearch in Google Scholar

29. Di Minno MND, Ambrosino P, Franchini M, Coppola A, Di Minno G. Arthropathy in patients with moderate hemophilia a: a systematic review of the literature. Semin Thromb Hemost 2013; 39: 723–31. doi: 10.1055/s-0033-1354422. Di MinnoMND AmbrosinoP FranchiniM CoppolaA Di MinnoG Arthropathy in patients with moderate hemophilia a: a systematic review of the literature Semin Thromb Hemost 2013 39 723 31 10.1055/s-0033-1354422 Open DOISearch in Google Scholar

30. Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost 2021; 19: 2112–21. doi: 10.1111/jth.15444. GualtierottiR SolimenoLP PeyvandiF Hemophilic arthropathy: Current knowledge and future perspectives J Thromb Haemost 2021 19 2112 21 10.1111/jth.15444 Open DOISearch in Google Scholar

31. Mannucci PM. Hemophilia therapy: the future has begun. Haematologica 2020; 105: 545–53. doi: 10.3324/haematol.2019.232132. MannucciPM Hemophilia therapy: the future has begun Haematologica 2020 105 545 53 10.3324/haematol.2019.232132 Open DOISearch in Google Scholar

32. Nazir H, khanbashi L, Wali Y, et al. Screening for inhibitor development and its risk factors in patients with severe haemophilia a in Oman. Hematol Transfus Int J 2018; 6: 87–90. doi: 10.15406/htij.2018.06.00159. NazirH khanbashiL WaliY Screening for inhibitor development and its risk factors in patients with severe haemophilia a in Oman Hematol Transfus Int J 2018 6 87 90 10.15406/htij.2018.06.00159 Open DOISearch in Google Scholar

33. Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606–12. doi: 10.1111/j.1365-2516.2007.01518.x. MorfiniM HayaS TagarielloG European study on orthopaedic status of haemophilia patients with inhibitors Haemophilia 2007 13 606 12 10.1111/j.1365-2516.2007.01518.x Open DOISearch in Google Scholar